FDA Grants Fast Track Designation to Corbus Pharmaceuticals' CRB-701 for HNSCC Treatment.

Corbus Pharmaceuticals Holdings has received Fast Track designation from the FDA for CRB-701, an antibody drug conjugate targeting Nectin-4, for the treatment of recurrent or metastatic head and neck squamous cell carcinoma and relapsed or refractory metastatic cervical cancer. The company plans to present dose optimization data from its Phase 1/2 study at ESMO 2025.